CN Patent

CN109153666B — 吲哚衍生物及其作为蛋白激酶抑制剂的用途

Assigned to Respivert Ltd · Expires 2021-07-16 · 5y expired

What this patent protects

本发明特别涉及式(I)化合物，其中R1、R2和R3如说明书中所定义，并且涉及包含所述化合物的组合物，以及涉及所述化合物和所述化合物的组合物在治疗中、例如在治疗纤维化疾病或间质性肺病、特别是特发性肺纤维化中的用途。

USPTO Abstract

本发明特别涉及式(I)化合物，其中R1、R2和R3如说明书中所定义，并且涉及包含所述化合物的组合物，以及涉及所述化合物和所述化合物的组合物在治疗中、例如在治疗纤维化疾病或间质性肺病、特别是特发性肺纤维化中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN109153666B
Jurisdiction
CN
Classification
—
Expires
2021-07-16
Drug substance claim
No
Drug product claim
No
Assignee
Respivert Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.